泰德制药：自主研发的利多卡因凝胶贴膏获批上市

Core Viewpoint - The approval of Lidocaine Gel Patch (brand name: Debain) by the National Medical Products Administration marks a significant milestone for Tide Pharmaceutical in the treatment of diabetic peripheral neuropathic pain (DPNP) [1] Company Overview - Tide Pharmaceutical has over 20 years of experience in transdermal formulation technology, focusing on this core area to build a leading modern transdermal technology platform and product matrix in China [1] - The company has successfully launched several products, including: - Fluorobuprofen Gel Patch (Debian) in 2010, capturing 90% of the domestic hospital external analgesic market with annual sales exceeding 30 billion [1] - Debain in 2018, filling a gap in external treatment for postherpetic neuralgia [1] - Suledar, an Alzheimer's treatment patch, recognized upon its initial launch in 2024 [1] - Deritro, a cough and asthma relief patch, expected to launch in 2025 [1] - Recently approved Rotigotine Parkinson's patch (Rofidin), enhancing the company's presence in the neurological field [1] Product Development Strategy - Tide Pharmaceutical plans to launch 14 transdermal delivery products by 2030, continuously improving its product layout through a strategy of "star-led, tiered collaboration" [1]